NovoCure Ltd·4

Jun 4, 4:09 PM ET

Leonard Frank X 4

4 · NovoCure Ltd · Filed Jun 4, 2025

Insider Transaction Report

Form 4
Period: 2025-06-02
Leonard Frank X
Chief Executive Officer
Transactions
  • Sale

    Ordinary Shares

    2025-06-02$17.99/sh6,600$118,733170,331 total
  • Sale

    Ordinary Shares

    2025-06-02$17.22/sh21,717$373,958176,931 total
  • Sale

    Ordinary Shares

    2025-06-02$19.01/sh1,879$35,722168,452 total
Footnotes (3)
  • [F1]On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 21,717 shares in multiple trades at prices ranging from $16.71 to $17.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
  • [F2]On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,600 shares in multiple trades at prices ranging from $17.71 to $18.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 1,879 shares in multiple trades at prices ranging from $18.78 to $19.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT